Drug or treatment

Daratumumab clinical trials

• 64Clinical trials
• 1New in 30 days
• 39Countries

Newest trials

All recruiting trials (64)

• Fewer-doses daratumumab added to VRd for newly diagnosed multiple myeloma

  This study tests whether a less-frequent daratumumab dosing plan added to VRd can help patients with newly diagnosed multiple myeloma achieve more MRD negativity.

  Recruiting Phase 2 Tata Memorial Centre · Navi Mumbai, Maharashtra and 1 other locations · NCT07891923

• BCD-248 plus daratumumab in relapsed or refractory multiple myeloma

  This study tests whether adding BCD-248 to daratumumab helps people with relapsed or refractory multiple myeloma who have had prior lines of therapy.

  Recruiting at 16 sites Phase 3 Biocad · Homyel and 15 other locations · NCT07742215

• Tec Dara for newly diagnosed multiple myeloma with light chain amyloidosis

  This study tests whether tec listamab plus daratumumab can help newly diagnosed multiple myeloma with AL amyloidosis and whether the combination is safe.

  Recruiting Phase 2 Shanghai Zhongshan Hospital · Shanghai · NCT07638683

• Daratumumab for acquired immune thrombotic thrombocytopenic purpura

  This project tests whether daratumumab can raise ADAMTS13 activity in adults with acquired (immune) TTP who did not respond to or could not tolerate standard immunosuppressive treatments.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT07513948

• A combination therapy for teens and young adults with relapsed or refractory T-ALL/T-LBL

  This phase 1 study tests a four-drug regimen (venetoclax, dexamethasone, bortezomib, and daratumumab) in adolescents and young adults whose T-cell ALL or T-cell lymphoblastic lymphoma has come back or not responded.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT07513129

• Maintaining myeloma with less frequent daratumumab plus lenalidomide

  This phase 2 study tests a reduced-dosing schedule of daratumumab with lenalidomide to maintain remission in adults with multiple myeloma after stem cell transplant.

  Recruiting Phase 2 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07485647

• GR1803 injection versus daratumumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma

  This trial tests whether GR1803 injection works better than daratumumab combined with pomalidomide and dexamethasone for adults with relapsed or refractory multiple myeloma who have had one to three prior treatments.

  Recruiting Phase 3 Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Tianjin · NCT07452198

• Linvoseltamab vs. Daratumumab in high-risk smoldering myeloma

  This study tests whether linvoseltamab can delay progression to active myeloma better than daratumumab in people with high-risk smoldering multiple myeloma.

  Recruiting at 33 sites Phase 3 Regeneron Pharmaceuticals · Phoenix, Arizona and 32 other locations · NCT07393282

• Daratumumab versus rituximab for children with primary immune thrombocytopenia

  This study will test whether daratumumab works better than rituximab to increase platelet counts in children aged 6–17 with primary ITP who did not respond to or relapsed after steroid treatment.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT07362238

• Sonrotoclax plus dexamethasone with or without daratumumab for t(11;14) AL amyloidosis

  This study tests whether adding sonrotoclax (a BCL-2 inhibitor) to dexamethasone, with or without daratumumab, helps people with t(11;14) positive AL amyloidosis.

  Recruiting at 2 sites Phase 2 Peking University People's Hospital · Beijing and 2 other locations · NCT07335887

• Daratumumab for refractory aplastic anemia in adults

  This trial tests whether daratumumab can be safely given and help people with refractory aplastic anemia see a benefit.

  Recruiting Phase 1/2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07287228

• Belantamab Mafodotin or Daratumumab with VRd for Newly Diagnosed High-Risk Myeloma

  This study tests whether belantamab mafodotin plus standard multiple myeloma drugs works better than daratumumab plus the same drugs for people newly diagnosed and ineligible for transplant.

  Recruiting Phase 3 PrECOG, LLC. · La Crosse, Wisconsin · NCT07285239

• FT836 CAR T-cell Therapy with Daratumumab in relapsed/refractory multiple myeloma

  This phase 1 study tests whether FT836 CAR T cells given with daratumumab are safe and show early signs of activity in adults with relapsed or refractory multiple myeloma who have had at least three prior therapies.

  Recruiting Phase 1 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT07221032

• Teclistamab plus daratumumab for newly diagnosed AL amyloidosis

  This tests whether combining teclistamab with daratumumab is safe and helps people newly diagnosed with AL amyloidosis by lowering harmful light chains and protecting organ function.

  Recruiting at 2 sites Phase 2 Columbia University · Boston, Massachusetts and 2 other locations · NCT07110844

• Daratumumab combined with teclistamab or talquetamab for frail adults with newly diagnosed multiple myeloma

  This study will test whether adding teclistamab or talquetamab to daratumumab helps frail adults newly diagnosed with multiple myeloma remain progression-free at 18 months.

  Recruiting at 6 sites Phase 2 European Myeloma Network B.V. · Ascoli Piceno and 28 other locations · NCT07107529

• Etentamig plus daratumumab versus daratumumab‑lenalidomide‑dexamethasone for newly diagnosed multiple myeloma in patients not eligible for transplant

  This trial will test whether adding the investigational drug etentamig to daratumumab helps control disease and is safe in adults newly diagnosed with multiple myeloma who cannot have a transplant.

  Recruiting at 49 sites Phase 2/3 AbbVie · Scottsdale, Arizona and 48 other locations · NCT07095452

• Daratumumab-hyaluronidase added to your myeloma treatment to see if it helps kidney function

  This trial tests whether adding daratumumab-hyaluronidase to the standard bortezomib and dexamethasone therapy improves kidney function in adults newly diagnosed with multiple myeloma and kidney failure.

  Recruiting Phase 2 Eastern Cooperative Oncology Group · Anchorage, Alaska · NCT07085728

• Daratumumab for late antibody-mediated rejection in kidney transplant recipients with new donor-specific antibodies

  This research tests whether daratumumab can help kidney transplant recipients who develop late antibody-mediated rejection after forming new donor-specific antibodies.

  Recruiting University Hospital, Martin · Martin · NCT07081126

• Subcutaneous daratumumab in the thigh versus the abdomen for adults with plasma cell disorders

  This trial tests whether giving subcutaneous daratumumab in the thigh instead of the abdomen is safe and gives similar blood levels in adults with multiple myeloma or AL amyloidosis starting daratumumab.

  Recruiting Phase 1/2 University of Maryland, Baltimore · Baltimore, Maryland · NCT07075510

• Anti-CD38 antibody treatment for elderly people with primary immune thrombocytopenia

  This trial will try the anti-CD38 antibody daratumumab to raise platelet counts in people aged 60 and older with primary ITP who have not responded to multiple treatments.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07063199

• Daratumumab to clear leftover T‑cell acute lymphoblastic leukemia

  This trial will try daratumumab given by IV to see if it can clear leftover cancer (MRD) in adults with T‑ALL who remain MRD‑positive after two induction cycles.

  Recruiting Phase 2 Tata Memorial Centre · Navi Mumbai, Maharashtra · NCT07021677

• Daratumumab‑hyaluronidase plus teclistamab vs standard daratumumab combinations for high‑risk relapsed or refractory multiple myeloma

  This phase 2 trial tests whether combining daratumumab with teclistamab helps people with high‑risk myeloma that has not responded to treatment or has come back, compared to usual daratumumab‑based therapies.

  Recruiting at 32 sites Phase 2 National Cancer Institute (NCI) · Coeur d'Alene, Idaho and 31 other locations · NCT06948084

• Linvoseltamab versus standard daratumumab‑lenalidomide‑dexamethasone for adults with newly diagnosed, transplant‑ineligible multiple myeloma

  This trial tests whether linvoseltamab works better or is safer than the standard daratumumab‑lenalidomide‑dexamethasone combination in adults newly diagnosed with multiple myeloma who are not eligible for transplant.

  Recruiting at 59 sites Phase 3 European Myeloma Network B.V. · Adelaide and 58 other locations · NCT06932562

• Effect of Daratumumab on Kidney Diseases Related to Monoclonal Gammopathy

  This study is testing whether daratumumab can help improve kidney function and overall health in people with kidney diseases linked to monoclonal gammopathy.

  Recruiting Phase 2 Helsinki University Central Hospital · Helsinki · NCT06889948

• Combining B Cell Depletion Therapy with Daratumumab for Autoimmune Encephalitis

  This study is testing a new treatment that combines two therapies to see if it can help people with severe autoimmune encephalitis feel better by targeting harmful cells in their bodies.

  Recruiting at 2 sites Phase 3 The First People's Hospital of Changzhou · Zhengzhou, Henan and 1 other locations · NCT06867991

• Combination treatment for relapsed multiple myeloma using iberdomide, daratumumab, elotuzumab, and dexamethasone

  This study is testing a new combination of four medications to see if it can help people with relapsed multiple myeloma feel better and live longer.

  Recruiting Phase 1/2 Mayo Clinic · Rochester, Minnesota · NCT06785415

• Combining JNJ-79635322 with Daratumumab or Pomalidomide for Multiple Myeloma Treatment

  This study is testing a new drug called JNJ-79635322 combined with either daratumumab or pomalidomide to see how safe and effective it is for people with multiple myeloma.

  Recruiting at 16 sites Phase 1 Janssen Research & Development, LLC · Denver, Colorado and 15 other locations · NCT06768489

• Evaluating a new treatment approach for primary plasma cell leukemia

  This study is testing a new treatment plan that combines two drugs for people who have just been diagnosed with primary plasma cell leukemia to see if it helps them feel better and live longer.

  Recruiting at 7 sites Phase 2 Hellenic Society of Hematology · Athens, Attica and 6 other locations · NCT06636552

• Predicting organ response in AL amyloidosis treatment

  This study is testing if measuring the quick response of certain proteins in the blood can help predict how well patients with AL amyloidosis will respond to treatment with daratumumab, bortezomib, and dexamethasone.

  Recruiting at 8 sites Peking University People's Hospital · Beijing, Beijing Municipality and 7 other locations · NCT06627309

• Combining SX-682 with standard treatments for relapsed or refractory multiple myeloma

  This study is testing if adding a new drug called SX-682 to standard treatments can help people with relapsed or refractory multiple myeloma feel better and fight their cancer more effectively.

  Recruiting Phase 1 Roswell Park Cancer Institute · Buffalo, New York · NCT06622005

• Comparing two treatment options for elderly patients with newly diagnosed multiple myeloma

  This study is testing two different treatment options for older patients with newly diagnosed multiple myeloma to see which one works better and is safer.

  Recruiting at 6 sites The First Affiliated Hospital with Nanjing Medical University · Changzhou, Jiangsu and 5 other locations · NCT06497738

• Treatment for newly diagnosed monoclonal immunoglobulin deposition disease

  This study is testing a new combination treatment for people who have just been diagnosed with monoclonal immunoglobulin deposition disease to see if it helps improve their blood health.

  Recruiting at 3 sites Phase 2 Peking University People's Hospital · Beijing, Beijing Municipality and 2 other locations · NCT06418477

• Using Darzalex Faspro to lower antibody levels before stem cell transplant

  This study is testing if a new treatment called Darzalex Faspro can help lower harmful antibodies in adults so they can safely receive a stem cell transplant for blood cancers.

  Recruiting Early Phase 1 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT06398457

• Using daratumumab to treat patients with light chain amyloidosis

  This study is testing how well daratumumab works for treating light chain amyloidosis in different groups of patients to find the best way to help them.

  Recruiting Nanjing University School of Medicine · Nanjing, Jiangsu · NCT06376214

• Transplant for Sickle Cell Disease Using a Nonmyeloablative Approach

  This study is testing a new way to help people with sickle cell disease who have certain antibodies receive a safer type of stem cell transplant from a sibling to see if it can improve their chances of recovery.

  Recruiting Phase 2 Children's National Research Institute · Washington D.C., District of Columbia · NCT06358638

• Using a new antibody treatment with chemotherapy and radiation for high-risk blood cancers before stem cell transplant

  This study is testing a new antibody treatment combined with chemotherapy and radiation to see if it can help people with high-risk blood cancers before they receive a stem cell transplant.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT06287944

• Daratumumab with pomalidomide and dexamethasone for first-relapse multiple myeloma

  This will follow people with first-relapse multiple myeloma who receive daratumumab plus pomalidomide and dexamethasone to see if they go longer before the next progression than people on other contemporary regimens.

  Recruiting The First Hospital of Jilin University · Changchun, Jilin · NCT06252792

• Evaluating a treatment-free interval for newly diagnosed multiple myeloma patients

  This study is testing if taking a break from treatment can help newly diagnosed multiple myeloma patients manage their disease while feeling better and having fewer side effects.

  Recruiting at 38 sites Phase 3 Stichting Hemato-Oncologie voor Volwassenen Nederland · 's-Hertogenbosch and 37 other locations · NCT06187441

• Treatment for newly diagnosed double-hit multiple myeloma

  This study is testing a new treatment plan for people with newly diagnosed double-hit multiple myeloma to see if it helps them get better and stay in remission after a stem cell transplant.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT06158269

• Induction treatment for newly diagnosed multiple myeloma patients with renal failure

  This study is testing a new treatment plan for people with newly diagnosed multiple myeloma and kidney problems to see if it helps them respond better to therapy.

  Recruiting Early Phase 1 Augusta University · Augusta, Georgia · NCT06142396

• Evaluating a new treatment for ultra high-risk multiple myeloma patients

  This study is testing a new treatment plan for patients with ultra high-risk multiple myeloma to see if it can help them live longer and respond better to therapy.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT06140966

• Using Iberdomide and Daratumumab for Maintenance After Stem Cell Transplant in Multiple Myeloma

  This study is testing if a combination of Iberdomide and Daratumumab can help people with Multiple Myeloma who still have some disease after a stem cell transplant feel better and live longer.

  Recruiting at 2 sites Phase 2 Barbara Ann Karmanos Cancer Institute · Detroit, Michigan and 1 other locations · NCT06107738

• Combination treatment for high-risk smoldering multiple myeloma

  This study is testing two different combination treatments to see which one helps people with high-risk smoldering multiple myeloma delay their disease from getting worse.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT06100237

• Combining CyBorD with Daratumumab for treating kidney disease related to monoclonal gammopathy

  This study is testing a new treatment combining CyBorD and daratumumab to see if it can help people with kidney disease caused by monoclonal gammopathy feel better and improve their kidney function.

  Recruiting at 8 sites Phase 2 Memorial Sloan Kettering Cancer Center · Boston, Massachusetts and 10 other locations · NCT06083922

• Comparing chemotherapy with and without stem cell transplant for AL amyloidosis

  This study is testing whether adding a stem cell transplant to chemotherapy can help people with newly diagnosed AL amyloidosis live longer and have better organ health.

  Recruiting at 116 sites Phase 3 SWOG Cancer Research Network · Goodyear, Arizona and 116 other locations · NCT06022939

• Daratumumab treatment for aggressive lymphoma

  This study tests if daratumumab injections can help adults with a rare and aggressive type of lymphoma that hasn't responded to other treatments.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT05907759

• Daratumumab maintenance therapy for AL amyloidosis

  This study tests whether shorter or longer maintenance therapy with daratumumab helps people with light chain amyloidosis stay healthy after their initial treatment.

  Recruiting at 2 sites Phase 2 Mayo Clinic · Scottsdale, Arizona and 1 other locations · NCT05898646

• Combination therapy for relapsed or refractory multiple myeloma

  This study is testing a new combination of medications to see if it can help people with relapsed or refractory multiple myeloma feel better and improve their treatment results.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT05896228

• Treatment for Hemophilia A in Adolescents and Adults with High Titer Inhibitor

  This study is testing if a new treatment for hemophilia A, using a drug called SCT800 alone or with another drug called Daratumumab, can help teenagers and adults with high titer inhibitors feel better and have fewer relapses.

  Recruiting Phase 4 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT05888870

• Using a CD38 antibody with corticosteroids to treat acquired hemophilia A

  This study is testing if a combination of a new antibody treatment and steroids can help people with acquired hemophilia A stop bleeding and stay healthy.

  Recruiting Phase 4 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT05849740

• Daratumumab with induction chemo in older adults with poor-risk AML

  This study tests whether giving daratumumab together with standard induction chemotherapy is safe and helps older adults with poor-prognosis AML reach an effective dose.

  Recruiting Phase 1 Nantes University Hospital · Nantes · NCT05749276

• Using daratumumab to treat Primary Antiphospholipid Syndrome

  This study is testing if daratumumab can safely help people with Primary Antiphospholipid Syndrome feel better.

  Recruiting at 7 sites Phase 1/2 National Institute of Allergy and Infectious Diseases (NIAID) · Baltimore, Maryland and 7 other locations · NCT05671757

• Evaluating new treatment combinations for newly diagnosed multiple myeloma patients not eligible for transplant

  This study is testing different combinations of medications for people with newly diagnosed multiple myeloma who can't have a transplant to see which one works best and is safest.

  Recruiting at 170 sites Phase 3 Pfizer · Daphne, Alabama and 179 other locations · NCT05623020

• Combining teclistamab and talquetamab with daratumumab and lenalidomide for newly diagnosed multiple myeloma

  This study is testing two new treatment combinations for people with newly diagnosed multiple myeloma to see if they work better than the standard treatment.

  Recruiting at 66 sites Phase 3 Janssen Research & Development, LLC · Gilbert, Arizona and 269 other locations · NCT05552222

• Daratumumab with indium‑111 and actinium‑225 radioimmunotherapy for relapsed or refractory multiple myeloma

  This trial will see if combining daratumumab with indium‑111 and actinium‑225 labeled daratumumab is safe and may help adults whose multiple myeloma has returned or stopped responding to prior treatments.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT05363111

• Using daratumumab to treat T-cell leukemia that doesn't respond to chemotherapy

  This study is testing if daratumumab can help T-cell leukemia patients who haven't responded to chemotherapy by seeing if it clears their cancer and improves their chances of staying healthy.

  Recruiting Phase 2 Eastern Cooperative Oncology Group · Chicago, Illinois · NCT05289687

• Elranatamab alone or with daratumumab for people with multiple myeloma after prior treatment

  This trial will test whether the BCMA-targeting drug elranatamab alone or together with daratumumab helps people with multiple myeloma who have already been treated with lenalidomide, compared with daratumumab plus pomalidomide and dexamethasone.

  Recruiting at 80 sites Phase 3 Pfizer · Clovis, California and 236 other locations · NCT05020236

• Testing sonrotoclax alone and with other treatments for multiple myeloma

  This study is testing a new treatment called sonrotoclax, alone and with other medications, to see if it helps people with a specific type of multiple myeloma that has come back or hasn’t responded to other treatments.

  Recruiting at 64 sites Phase 1/2 BeOne Medicines · Birmingham, Alabama and 73 other locations · NCT04973605

• Targeted immunotherapy for high-risk T-cell leukemia and lymphoma in young patients

  This study is testing a new treatment called daratumumab for young patients with high-risk T-cell leukemia and lymphoma to see if it is safe and helps improve their outcomes after a stem cell transplant.

  Recruiting at 8 sites Phase 1 New York Medical College · Phoeniz, Arizona and 15 other locations · NCT04972942

• Evaluating a treatment combining Daratumumab, Bortezomib, and Dexamethasone for Plasmablastic Lymphoma

  This study is testing a new combination treatment of Daratumumab, Bortezomib, and Dexamethasone to see if it helps people with relapsed or hard-to-treat Plasmablastic Lymphoma.

  Recruiting at 14 sites Phase 2 Fondazione Italiana Linfomi - ETS · Ancona, Ancona and 17 other locations · NCT04915248

• Cevostamab in relapsed or refractory multiple myeloma

  This early-stage trial tests cevostamab alone or with standard therapies to see if it is safe and how it behaves in people with relapsed or refractory multiple myeloma.

  Recruiting at 4 sites Phase 1 Genentech, Inc. · Duarte, California and 33 other locations · NCT04910568

• Selinexor in Combination With Carfilzomib, Daratumumab, or Pomalidomide in Multiple Myeloma

  This study tests whether adding selinexor to existing myeloma treatments (carfilzomib, pomalidomide, or daratumumab) helps patients whose disease has progressed or become resistant to those therapies.

  Recruiting at 2 sites Phase 2 Hackensack Meridian Health · Washington D.C., District of Columbia and 1 other locations · NCT04661137

• Daratumumab plus dose-adjusted EPOCH for plasmablastic lymphoma

  This treatment tries adding the antibody daratumumab to DA-EPOCH chemotherapy to see if it helps people with newly diagnosed stage I–IV plasmablastic lymphoma.

  Recruiting at 9 sites Early Phase 1 AIDS Malignancy Consortium · Miami, Florida and 8 other locations · NCT04139304

• Combining lenalidomide and dexamethasone with or without daratumumab for high-risk smoldering myeloma

  This study is testing if adding daratumumab to the standard treatment of lenalidomide and dexamethasone can help people with high-risk smoldering multiple myeloma live longer and feel better.

  Recruiting at 489 sites Phase 3 Eastern Cooperative Oncology Group · Birmingham, Alabama and 747 other locations · NCT03937635

Quick answers

How many clinical trials of Daratumumab are recruiting right now?

64, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 39 countries. The most sites are in United States (36 trials), China (20 trials), Italy (9 trials), Spain (9 trials), France (8 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 26, Phase 3: 12, Phase 1: 9, Phase 1/2: 5. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →